Participants will receive a series of study visits over about two years. During the visits, the assigned treatment (either the medicine or the control solution) is administered by IV infusion at set intervals, and simple tests of thinking, memory and daily functioning are performed to check for any changes. Safety checks, such as blood tests and heart monitoring, are also done regularly to ensure the treatment is well tolerated. The overall design of the trial keeps both the participants and the study staff unaware of which treatment is being given, to provide an unbiased comparison.

The research compares single antiplatelet therapy (SAPT) with dual antiplatelet therapy (DAPT). Antiplatelet medications help prevent blood clots from forming. The purpose is to determine if using just one antiplatelet medication is as effective as using two in preventing complications after the procedure, while potentially reducing bleeding risks.

The study will follow patients for 12 months after their procedure to track outcomes such as death from any cause, the need for additional procedures on the treated blood vessel, and heart attacks related to the treated vessel. Quality of life and functional status will be assessed using questionnaires at different timepoints throughout the study.

The purpose of the study is to evaluate the safety and initial effectiveness of the NVD-003 implant in helping bones heal. Participants in the study will receive the implant through a surgical procedure. After the surgery, they will be monitored over a period of time to check for any side effects and to see how well the bone is healing. This will involve regular check-ups and imaging tests like X-rays and CT scans to assess the progress of bone healing.

Throughout the study, the participants’ overall health and quality of life will also be evaluated. This includes monitoring pain levels and any changes in daily activities. The study aims to provide valuable information on whether this new treatment can be a safe and effective option for people with this challenging bone condition.

The purpose of this study is to evaluate how effective prasinezumab is compared to a placebo in delaying the progression of motor symptoms in people with early Parkinson’s disease. Participants in the study will receive either prasinezumab or a placebo through IV infusions. The study will monitor the time it takes for participants to experience a confirmed worsening of their motor symptoms. This will help researchers understand if prasinezumab can slow down the progression of the disease.

Throughout the study, participants will be regularly assessed to track any changes in their motor function and overall health. This includes monitoring for any side effects or adverse reactions to the treatment. The study aims to provide valuable information on the safety and effectiveness of prasinezumab for individuals with early Parkinson’s disease, potentially leading to better treatment options in the future.

The purpose of this study is to document the long-term safety of the NVDX3 implant. Participants in the study will have previously been involved in core clinical trials with NVDX3 and will continue to be monitored for safety over a period of 10 additional years. This involves yearly follow-up visits to ensure the implant remains safe for use over a long period. The study will collect information on any serious adverse events (SAEs) or other side effects related to the implant from the time of screening until 10 years after the initial study.

Participants in this study will have agreed to these follow-up visits and will have signed an informed consent form to confirm their understanding and willingness to participate in this long-term safety study. The study aims to provide valuable information on the safety of the NVDX3 implant for patients with the specified conditions, contributing to the understanding of its long-term effects and potential benefits.

The purpose of the study is to determine if baricitinib can help reduce the risk of death in patients with severe or critical COVID-19. Participants in the study will receive either the medication or a placebo, and their health will be monitored to see how the disease progresses. The study will look at whether the medication can prevent the disease from getting worse and if it can help patients recover more quickly.

Throughout the study, participants will be closely observed to track their recovery and any changes in their condition. The trial will also assess various health markers to understand the impact of the treatment. This research is part of a larger effort to find effective treatments for COVID-19 and improve outcomes for patients with this disease.

The purpose of the study is to evaluate how effective Bemcentinib is in improving the condition of patients with moderate COVID-19. Participants in the study will receive either Bemcentinib or a placebo, along with the usual care provided in hospitals. The study will monitor the patients’ health over a period of time to see if there are any changes in their condition, such as improvement or worsening of symptoms. The study will also look at other factors, such as how quickly patients recover and any side effects they may experience.

Throughout the study, various health indicators will be assessed, including the patients’ disease state on a scale used by the World Health Organization (WHO) and the levels of oxygen in their blood. The study will also track the occurrence of any serious health events and the time it takes for patients to be discharged from the hospital. By the end of the study, researchers hope to gather valuable information about the potential benefits and safety of using Bemcentinib to treat COVID-19.

The purpose of the study is to evaluate how well this combination of treatments works in patients with ES-SCLC. Participants in the study will receive these medications over a period of time, with durvalumab being administered for up to 48 weeks and the other medications for up to 12 weeks. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study will monitor participants’ health and response to the treatment, including their overall survival and any changes in their quality of life. The goal is to determine if this combination of treatments can improve outcomes for patients with this type of lung cancer. Participants will be closely observed for any side effects or adverse reactions to the medications throughout the study period.